References
- Scharman EJ, Erdman AR, Cobaugh DJ, Olson KR, Woolf AD, Caravati EM, Chyka PA, Booze LL, Manoguerra AS, Nelson LS, Christianson G, Troutman WG. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45:737–752.
- US Food and Drug Administration, Pediatric Advisory Committee. Briefing information. 30 June 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4152b2.htm [accessed November 25, 2009].
- Medicines and Healthcare Products Regulatory Agency. Summary of the meeting of the Pharmacovigilance Expert Advisory Group held on 7 November 2007. http://www.mhra.gov.uk/home/groups/l-cs-el/documents/committeedocument/con2033716.pdf [accessed November 25, 2009].
- US Food and Drug Administration. Drug Safety and Risk Management Advisory Committee Meeting. 9–10 February 2006. http://www.fda.gov/ohrms/DOCKETS/ac/06/transcripts/2006-4202t1.pdf [accessed November 25, 2009].
- Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166:992–1001.
- European Medicines Agency. ICH Topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhythmic drugs. http://www.emea.europa.eu/pdfs/human/ich/000204en.pdf [accessed November 25, 2009].
- Wakamatsu A, Nomura S, Tate Y, Shimizu S, Harada Y. Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods 2009; 59:128–134.
- Ilgenli TF, Congologlu A, Ozturk C, Turkbay T, Akpinar O, Kilicaslan F. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Adv Ther 2007; 24:182–188.
- Pekdemir H, Toros F, Çamsarı A, Çicek D, Yurtdaş M, Parmaksız T, Katırcıbaşıi T. The effect of methylphenidate on cardiovascular functions in the treatment of attention deficit hyperactivity disorder. Çocuk ve Gençlik Ruh Sagligi Dergisi (J Child Adolesc Ment Health) 2003; 10:9–16.
- Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802–805.
- Desai M, Li L, Zeruesenay D, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2003; 55:511–517.
- Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QT interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048–1052.
- Isbister GK, Friberg LE, Duffull SB. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med 2006; 32:1060–1065.
- Foley R, Mrvos R, Krenzelok EP. A profile of methylphenidate exposures. Clin Toxicol 2000; 38:625–630.
- Klein-Schwartz W. Pediatric methylphenidate exposures: 7-year experience of poison centers in the United States. Clin Pediatr (Phila) 2003; 42:159–164.
- Klein-Schwartz W, McGrath J. Poison centers’ experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry 2003; 42:288–294.